Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Aisha Khan

Nurse Practitioner, Primary Care Schaumburg, IL Nurse Practitioner

NPI 1902588213 CMS profile 11513186

921 N Plum Grove Rd, Schaumburg, IL 60173

Open in the dashboard

General payments

$3,086

130 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Aisha Khan of Schaumburg, IL is reported in the CMS Open Payments database as having received $3,086 across 130 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,192 48
2024 General $1,657 72
2023 General $236 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aisha Khan
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Aisha Khan were reported at $1,192. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Aisha Khan Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $137 $39–$445 $132
2022 $0 $139 $44–$421 $149
2023 $236 $163 $53–$481 $160
2024 $1,657 $176 $54–$511 $164
2025 $1,192 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Lilly USA, LLC $622 26 payments
  2. AstraZeneca Pharmaceuticals LP $330 18 payments
  3. Novo Nordisk Inc $320 12 payments
  4. Dexcom, Inc. $319 12 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $168 7 payments
  6. AbbVie, Inc. $116 5 payments
  7. Medtronic, Inc. $101 1 payment
  8. Avadel CNS Pharmaceuticals, LLC $89 4 payments
  9. Sequel Med Tech, LLC $86 1 payment
  10. Corcept Therapeutics $85 3 payments
  11. Other $851 41 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $3,086 130 payments
Products named General payments · program years 2023–2025
  1. MOUNJARO $350 16 payments
  2. Dexcom G6 Transmitter $319 12 payments
  3. ZEPBOUND $315 11 payments
  4. AIRSUPRA $234 12 payments
  5. Ozempic $211 6 payments
  6. JARDIANCE Diabetes $171 8 payments
  7. SYNJARDY $121 5 payments
  8. MINIMED 780G $101 1 payment
  9. JARDIANCE Diabetes $97 4 payments
  10. LUMRYZ $89 4 payments
  11. Other $1,740 81 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

294

Median for Nurse Practitioner: 389

Drug cost

$13,238

Median for Nurse Practitioner: $21,885

Branded share of claims

14.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 12 $11,198
Gabapentin Generic 29 $337
Enalapril Maleate Generic 11 $252
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 19 $196
Atorvastatin Calcium Generic 21 $190
Fluticasone Propionate Generic 17 $176
Alendronate Sodium Generic 18 $163
Methylprednisolone Generic 28 $120
Azithromycin Generic 30 $107
Levothyroxine Sodium Generic 12 $87

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZEPBOUND
  • Lilly USA, LLC $185
$185 — —
MOUNJARO
  • Lilly USA, LLC $127
$127 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $112
$112 — —
JARDIANCE
  • Lilly USA, LLC $57
  • Boehringer Ingelheim Pharmaceuticals, Inc. $37
$94 — —
Korlym
  • Corcept Therapeutics $85
$85 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

130 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Primary Care in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record